# Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism

> **NCT06531941** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MBX Biosciences** · enrollment: 60 (actual)

## Conditions studied

- Hypoparathyroidism

## Interventions

- **DRUG:** 400 µg of MBX 2109 once-weekly by subcutaneous injection
- **DRUG:** 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection

## Key facts

- **NCT ID:** NCT06531941
- **Lead sponsor:** MBX Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-31
- **Primary completion:** 2027-05-27
- **Final completion:** 2027-05-27
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06531941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06531941, "Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06531941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*